EHP-101
EHP-101 (VCE-004.8) is a dual PPARγ/CB2 receptor agonist with significant anti-inflammatory properties. It has been shown in research to inhibit adipogenesis and counteract diet-induced obesity in vivo, positioning it as a candidate for investigating metabolic and inflammatory disorders.
Product Specifications
CAS Number
1818428-24-8
Product Name Alternative
CB, CB2, Cannabinoid Receptor, CannabinoidReceptor, inhibit, Hypoxia-inducible factors, EHP 101, EHP101, EHP-101, Inhibitor, HIF, HIF/HIF ProlylHydroxylase, HIF Prolyl-Hydroxylase, HIF ProlylHydroxylase, HIFs, HIFProlylHydroxylase, HIF-PH, HIF/HIF Prolyl-Hydroxylase, HIF/HIFProlylHydroxylase, PPARγ, PPAR, Peroxisome proliferator-activated receptors, VCE-004.8, VCE-?004.8, VCE-004.8
Field of Research
Epigenetics & Chromatin, Metabolism Research, Molecular Biology, Pharmacology & Drug Discovery
Purity
98.36% (May vary between batches)
Solubility
DMSO:49 mg/mL (113.01 mM) ;10% DMSO+40% PEG300+5% Tween-80+45% Saline:2 mg/mL (4.61 mM)
Smiles
CCCCCC1=C (NCc2ccccc2) C (=O) C ([C@@H]2C=C (C) CC[C@H]2C (C) =C) =C (O) C1=O
Molecular Formula
C28H35NO3
Molecular Weight
433.58
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
